Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04177940 · ClinicalTrials.gov registry record · Phase 4
Denosumab (DMAB) Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis (GIOP): a Pilot Study
A Phase 4 study of Osteoporosis, sponsored by University of Alabama at Birmingham.
- Active
- Registry status
- Phase 4
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT04177940: Active Phase 4 study of Osteoporosis, sponsored by University of Alabama at Birmingham.
NCT04177940 is a Phase 4 study of Osteoporosis that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 45 participants, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04177940, a Phase 4 study of Osteoporosis, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators will test the hypothesis that an increase in bone turnover markers (e.g. carboxy-terminal collagen crosslinks (CTX) and P1NP) in patients currently taking chronic glucocorticoids will be attenuated more in those who switch from denosumab to "late" zoledronic acid (9 months after last denosumab dose) compared to participants randomized to "early" zoledronic acid (6 months after last denosumab dose) or weekly alendronate (6 months after last denosumab dose).
Primary Outcome
Absolute difference in the log-transformed CTX Values between randomization (V4) and 6 months after randomization (V6)
Conditions Studied
Interventions
- DRUG DMAB Discontinuation and Switching
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2020-08-17 |
| Est. Completion | 2025-08-31 |
| Phase | Phase 4 |
What the registry record for NCT04177940 still lists
NCT04177940 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Osteoporosis appearing as the primary indexed condition, and to 1 intervention - of which DMAB Discontinuation and Switching is the first listed.
NCT04177940 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT04177940 about?
NCT04177940 is a clinical study titled "Denosumab (DMAB) Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis (GIOP): a Pilot Study". Investigators will test the hypothesis that an increase in bone turnover markers (e.g. carboxy-terminal collagen crosslinks (CTX) and P1NP) in patients currently taking chronic glucocorticoids will be attenuated more in those who switch from denosumab to "late" zoledronic acid (9 months after last d...
What is the current status of trial NCT04177940?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 45 participants. The study started on 2020-08-17. Estimated completion is 2025-08-31.
What conditions does trial NCT04177940 study?
This clinical trial studies the following conditions: Osteoporosis.
What interventions are being tested in trial NCT04177940?
The interventions under investigation include: DMAB Discontinuation and Switching (DRUG).
Who is sponsoring clinical trial NCT04177940?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04177940 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04177940's enrollment target sits among peer trials
45 59th of 84 higher than 24 of 84 other Osteoporosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoporosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Preserving Geriatric Muscle With an Osteoporosis Medication
RECRUITING · Phase 4
-
Combined Anabolic Therapy
RECRUITING · Phase 4
-
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
ACTIVE NOT RECRUITING · Phase 4
-
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
ACTIVE NOT RECRUITING · Phase 4
-
Trial of Parkinson's And Zoledronic Acid
ACTIVE NOT RECRUITING · Phase 4
-
Muscle Impact of Treating Osteoporosis
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI